What should I discuss with the cardiovascular team about my possible heart failure with preserved ejection fraction (HFpEF) diagnosis, given my recent echocardiogram findings, iron‑deficiency anemia, chronic venous insufficiency, mild bilateral ankle edema, and difficulty obtaining an NT‑proBNP test, and what can I expect during the evaluation?

What to Discuss at Your Cardiovascular Center Visit

Your heart failure specialist's statement that you have "the physiology of HFpEF, not the syndrome" is an important distinction—you likely have cardiac structural/functional abnormalities consistent with HFpEF but don't yet meet full diagnostic criteria for the clinical syndrome of heart failure. This nuanced assessment warrants comprehensive evaluation at the cardiovascular center to clarify your diagnosis and optimize management. 1

Key Points to Communicate

Your Current Clinical Status

• Emphasize the specialist's exact wording: You have HFpEF physiology but are not currently in heart failure syndrome 1
• Detail your symptoms precisely: Describe any dyspnea, exercise intolerance, orthopnea, or nocturnal symptoms with specific functional limitations (e.g., how many blocks you can walk, stairs you can climb) 1
• Mention your bilateral ankle edema in the context of chronic venous insufficiency—this is critical because edema from venous disease can mimic HF signs 1
• Highlight your iron-deficiency anemia: This is a crucial comorbidity that affects approximately 50% of HF patients and can independently cause symptoms mimicking heart failure 2, 3

Diagnostic Clarification You Should Request

Request NT-proBNP or BNP testing at the cardiovascular center, as this is essential for diagnosis even though it's been difficult to obtain locally. 1 The Universal Definition of HF requires either elevated natriuretic peptides (NT-proBNP >125 pg/mL ambulatory) OR objective evidence of congestion. 1 However, be aware that:

• Natriuretic peptides can be falsely low in obesity (common in HFpEF) 1
• Your iron deficiency may affect interpretation of symptoms and biomarkers 3

Ask about diagnostic scoring systems to clarify your status:

• H2FPEF score: Incorporates obesity, atrial fibrillation, age >60, ≥2 antihypertensives, E/e' >9, and PA systolic pressure >35 mmHg. Scores ≥6 indicate high HFpEF likelihood; 2-5 requires further testing; <2 makes HFpEF unlikely 1
• HFA-PEFF algorithm: Uses functional, morphological, and biomarker domains with major (2 points) and minor (1 point) criteria. Scores ≥5 indicate definite HFpEF; ≤1 makes it unlikely; 2-4 requires exercise testing 4

Request exercise stress testing with echocardiography if your resting evaluation is inconclusive (score 2-5 on H2FPEF or 2-4 on HFA-PEFF). 1, 4 This can reveal elevated filling pressures during exertion that aren't apparent at rest—a common finding in early HFpEF. 1

What to Expect During Evaluation

Comprehensive Echocardiographic Assessment

The cardiovascular team will perform detailed echocardiography examining: 4

• Diastolic function parameters: E/e' ratio (elevated if ≥15), mitral annular velocity (e')
• Structural changes: Left atrial volume index, LV mass index, relative wall thickness
• Pulmonary pressures: Tricuspid regurgitation velocity
• LV global longitudinal strain: Can detect subtle systolic dysfunction despite preserved ejection fraction

Ruling Out HFpEF Mimics

The cardiovascular team's primary role is excluding alternative diagnoses that can present similarly to HFpEF: 1

• Cardiac mimics: Infiltrative cardiomyopathy (amyloidosis), hypertrophic cardiomyopathy, significant valvular disease, pericardial disease, high-output HF
• Non-cardiac causes: Your chronic venous insufficiency, pulmonary disease, deconditioning, anemia effects

Comorbidity Assessment and Management

Your iron-deficiency anemia requires specific attention as it:

• Affects approximately 50% of HF patients across all ejection fraction phenotypes 2, 3
• Is independently associated with worse symptoms and quality of life regardless of anemia presence 2, 3
• May warrant intravenous iron replacement even without anemia, which has shown benefit in both HFrEF and HFpEF 2
• Should be defined using transferrin saturation (TSAT) <20%, which shows the strongest prognostic associations and may be the preferred definition for treatment decisions 3

Expect discussion of other comorbidities that commonly coexist with HFpEF physiology: 5

• Atrial fibrillation
• Diabetes mellitus
• Chronic kidney disease
• Obesity

Treatment Considerations If HFpEF Is Confirmed

Guideline-Directed Medical Therapy (GDMT)

If you meet full HFpEF diagnostic criteria, expect discussion of SGLT2 inhibitors (sodium-glucose co-transporter-2 inhibitors), which now have Class 1 recommendations across the entire ejection fraction spectrum. 6 These improve quality of life and reduce HF hospitalizations in HFpEF. 6

Other potential therapies depending on your specific phenotype:

• Finerenone (nonsteroidal MRA) if you have diabetic chronic kidney disease 6
• Diuretics for congestion management if present 1
• Iron supplementation (likely intravenous) for your iron deficiency 2, 3

Important Caveats

• Beta-blockers should be discouraged in HFpEF unless indicated for specific comorbidities like atrial fibrillation or coronary disease 5
• Treatment of your chronic venous insufficiency is essential to distinguish cardiac from venous edema 1

Questions to Ask

1. "Do I meet full diagnostic criteria for HFpEF syndrome, or do I have subclinical disease?" 1
2. "What is my H2FPEF or HFA-PEFF score, and do I need exercise testing?" 1, 4
3. "Should I receive intravenous iron for my iron deficiency, and how should it be monitored?" 2, 3
4. "Are there clinical trials I'm eligible for?" (HF specialists specifically identify trial eligibility) 1
5. "How do we distinguish my ankle edema from venous insufficiency versus cardiac congestion?" 1
6. "What is my follow-up plan and when should I return to a cardiologist versus HF specialist?" 1

Referral Appropriateness

Your referral to a renowned cardiovascular center is appropriate given: 1

• Diagnostic uncertainty (HFpEF physiology without confirmed syndrome)
• Need for advanced testing (NT-proBNP, possible exercise testing)
• Multiple comorbidities requiring optimization (iron deficiency, venous insufficiency)
• Potential need for specialized HFpEF management if diagnosis is confirmed

The cardiovascular team will determine whether ongoing HF specialist follow-up is needed or if you can be managed by general cardiology with primary care. 1